Subcutaneous Immunoglobulin (SCIG) Industry Growth Expected to Reach $24.29 Billion by 2029 at a CAGR of 13.7% | Segmentation and Growth Opportunities
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has the Subcutaneous Immunoglobulin (SCIG) Market Growth Performance Trended Historically, And What Lies Ahead?_x000D_
In recent times, the subcutaneous immunoglobulin (SCIG) market has seen rapid expansion. The market size is projected to rise from $12.72 billion in 2024 to $14.52 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 14.1%. The expansion during the historical period has been driven by factors such as a heightened incidence of immunodeficiency ailments, an increase in patient inclination for home healthcare, improved therapeutic effectiveness, enhanced awareness and diagnosis rates, and progressive reimbursement policies._x000D_
_x000D_
#What Is the Forecast for the Subcutaneous Immunoglobulin (SCIG) Market Size Through 2029?#_x000D_
The market size for subcutaneous immunoglobulin (SCIG) is projected to experience considerable expansion in the coming years. It is forecasted to reach a worth of $24.29 billion in 2029, with a compound annual growth rate (CAGR) of 13.7%. This anticipated growth in the prediction period can be traced back to an increasing number of neurological disorders, a growing prevalence of autoimmune diseases, a surge in the acknowledgement and application of immunoglobulin therapy, as well as an expansion of its uses in neurology and dermatology, in addition to the growth of healthcare facilities. Significant trends for the forecast period encompass developments in drug delivery systems, a heightened demand for home-infused therapies, progress in antibody therapy, formulation advancements, and innovations specific to SCIG._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp_x000D_
_x000D_
#What are the Key Market Players in Subcutaneous Immunoglobulin (SCIG) Market and How They’re Evolving?#_x000D_
Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy’s Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc., Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc_x000D_
_x000D_
#What Are the Primary Growth Drivers in the Subcutaneous Immunoglobulin (SCIG) Market?#_x000D_
There is an expected surge in the subcutaneous immunoglobulin market due to an increased occurrence of secondary immunodeficiency diseases. These ailments result from an impaired immune system that is affected by external factors, not the immune system itself. This prevalence is amplified by factors such as an aging demographic, exposure to environmental toxins, and immunosuppressive therapies. Subcutaneous immunoglobulin treatment supplies antibodies to bolster a weakened immune system, specifically in chronic diseases like HIV or autoimmune disorders, thereby preventing infections and contributing to immune function during treatment. For instance, the UK Health Security Agency noted a 22% increase in new HIV diagnoses in England in 2022 compared to the previous year with 3,805 cases in October 2023. Hence, a rise in secondary immunodeficiency diseases is contributing towards the growth of the subcutaneous immunoglobulin market. The growth trend in the subcutaneous immunoglobulin market is also expected to be driven by the rising incidence of neurological disorders. These disorders, impacting the nervous system, encompass anatomical, biochemical, or electrical abnormalities in the brain, spinal cord, or peripheral nerves such as acute spinal cord injury, Alzheimer’s dementia, ALS, ataxia, brain tumors, among others. The escalation of neurological disorders can stem from factors like an aging population, ecological toxins, genetic susceptibility, and changes in lifestyle. Subcutaneous immunoglobulin therapy offers potential benefits in treating neurological disorders by offering antibodies that modulate the immune response, lessen inflammation, and establish neuromuscular junction stability, possibly decelerating disease advancement and ameliorating symptoms. According to the Alzheimer’s Association, in March 2022, it was reported that 6.5 million Americans over the age of 65 are currently living with Alzheimer’s dementia, with an estimated rise to 13.8 million by 2060. Therefore, the mounting number of neurological disorders is augmenting growth in the subcutaneous immunoglobulin market._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=15935&type=smp_x000D_
_x000D_
#What Are the Leading Segments in the Global Subcutaneous Immunoglobulin (SCIG) Industry?#_x000D_
The subcutaneous immunoglobulin (SCIG) market covered in this report is segmented –_x000D_
_x000D_
1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)_x000D_
2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications_x000D_
3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses_x000D_
_x000D_
Subsegments:_x000D_
1) By Immunoglobulin A (IgA): IgA1, IgA2_x000D_
2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4_x000D_
3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM_x000D_
_x000D_
#What Are the Key Market Trends in the Subcutaneous Immunoglobulin (SCIG) Industry?#_x000D_
Top-tier businesses in the subcutaneous immunoglobulin market are advancing their studies on subcutaneous human-klhw, a distinct preparation enriched with human immune globulins (Ig) designed to boost the immune system. The formulation is administered via the subcutaneous route, and is engineered to combat primary immunodeficiency diseases within humans. For instance, Grifols S.A., a pharmaceutical firm based in Spain, launched XEMBIFY 20% subcutaneous immunoglobulin (SCIG) in March 2022. This formulation is tailored specifically to manage primary immunodeficiency, responding to a key medical need of individuals with weak immune systems. The ready-to-use XEMBIFY simplifies treatment procedures and enhances patient compliance. Remarkably, it doesn’t require refrigeration as it can maintain stability at room temperature for up to 24 months. This characteristic can prove to be highly beneficial in diverse healthcare environments._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#What Is the Regional Outlook for the Subcutaneous Immunoglobulin (SCIG) Market?#_x000D_
North America was the largest region in the subcutaneous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15935_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the subcutaneous immunoglobulin (scig) market, and how is it changing globally?_x000D_
2. Who are the major companies in the subcutaneous immunoglobulin (scig) market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the subcutaneous immunoglobulin (scig) market right now?_x000D_
4. Which products or customer segments are growing the most in the subcutaneous immunoglobulin (scig) market?_x000D_
5. What factors are helping or slowing down the growth of the subcutaneous immunoglobulin (scig) market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 2071930708_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
